UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
February 7, 2008
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals to Present at the
10th
Annual BIO CEO & Investor Conference
VALLEY
COTTAGE, NEW YORK, February 7, 2008
- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) announced today that Ron
Bentsur, the Company’s Chief Executive Officer, is scheduled to present at the
10th Annual BIO CEO & Investor Conference. Mr. Bentsur will present an
overview of the Company including a discussion of Bicifadine, the Company’s
late-stage clinical compound for the treatment of diabetic neuropathic pain.
Mr.
Bentsur’s presentation will take place on Wednesday, February 13, 2008 at 1:15
pm EST at the Waldorf Astoria Hotel in New York City.
A
live
webcast of the presentation will be available at:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=XTL&item_id=1752502
An
archived version of the webcast will be available following the conclusion
of
the live presentation.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine,
a
serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic
neuropathic pain, which is currently in a Phase 2b study. XTL is also developing
novel pre-clinical HCV small molecule inhibitors. XTL also has an active
in-licensing and acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
||
| |
|
|
| Date: February 7, 2008 | By: | /s/ Bill Kessler |
|
Bill Kessler
|
||
|
Director
of Finance
|
||